LAMP1 and neoplasm: One of the first studies to demonstrate tumor specificity of TILRM was in the non-small cell lung cancer setting wherein the authors found that CD8+CD103+ TIL selectively upregulated CD107a and granzyme B in the presence of autologous tumor cells and also specifically lysed autologous tumor cells when co-cultured in the presence of an anti-PD-1 blocking antibody (39).